Survey to Describe Impact of Reflux Disease on Everyday Life in GERD Patients Before and After 4 Weeks Treatment.

AstraZeneca

Status: Completed

Conditions: Gastroesophageal Reflux Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT00786773

NIS-GVN-DUM-2008/1

Details and patient eligibility

About

To describe the change of impact of reflux symptoms on the everyday life perceived by patients before and after 4 weeks treatment by using GERD Impact Scale questionnaire (GIS) by total GERD patient population and by treatment group; and to describe the concordance between patient-reported and physician-reported symptom load.

Enrollment: 2,091 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with GERD diagnosed clinically or by endoscopy and prescribed with medical treatments
• Provision of written informed consent

Exclusion criteria

• Patients cannot read and/or understand GIS
• Patients with the history or symptoms of peptic ulcer, gastrointestinal cancer, serious or malignant diseases (anorexia, weight loss, anemia, fever ...)

Trial design

2,091 participants in 1 patient group

1

Description:

GERD patients who will be treated for GERD with PPI, H2RA, antacid, prokinetics, combination therapy